Expertise in
37
conditions

Dr. Ian W. Flinn

Tennessee Oncology PLLC
Tullahoma, TN
Expertise in
37
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
37
conditions
OverviewInsuranceLocationsClinical Research

Overview

Ian Flinn is a Hematologist Oncology specialist and a Hematologist in Tullahoma, Tennessee. Dr. Flinn is highly rated in 37 conditions, according to our data. His top areas of expertise are Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Flinn is currently accepting new patients.

His clinical research consists of co-authoring 172 peer reviewed articles and participating in 34 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Tristar Centennial Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Oscar
  •  US Health and Life
  •  Humana

Locations

TENNESSEE ONCOLOGY PLLC
1750 Cedar Ln, Suite 200, Tullahoma, TN 37388
615-333-2481

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drug: L-Bcl-2 Antisense Oligonucleotide
Study Phase: Phase 1
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.
A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: Nilotinib Followed by Treatment-Free
Study Phase: Phase 2
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
Enrollment Status: Enrolling_by_invitation
Publish Date: January 10, 2025
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: VAY736, Ibrutinib
Study Phase: Phase 1
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drugs: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2024
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
Enrollment Status: Suspended
Publish Date: November 13, 2023
Intervention Type: Other, Biological
Study Drug: MT-101
Study Phase: Phase 1/Phase 2
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Drug
Study Drug: TRPH-222
Study Phase: Phase 1
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 11, 2021
Intervention Type: Biological
Study Drugs: ACTR707, Rituximab
Study Phase: Phase 1
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Enrollment Status: Terminated
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia
Enrollment Status: Completed
Publish Date: February 09, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 31 Less Clinical Trials

177 Total Publications

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 08, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Brian I. Rini
Hematology Oncology | Oncology | Hematology
Expertise in
18
conditions
Dr. Brian I. Rini
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (61.5 mi)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Rini is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Rini is highly rated in 18 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Wilms Tumor, and Nephrectomy. Dr. Rini is currently accepting new patients.

Expertise in
38
conditions
Dr. Nishitha M. Reddy
Hematology Oncology | Oncology | Hematology
Expertise in
38
conditions
Dr. Nishitha M. Reddy
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (61.5 mi)
615-322-3000
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishitha Reddy is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Reddy is highly rated in 38 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reddy is currently accepting new patients.

Bipin N. Savani
Expertise in
26
conditions
Dr. Bipin N. Savani
Hematology Oncology | Transplant Surgery | Hematology
Expertise in
26
conditions
Dr. Bipin N. Savani
Hematology Oncology | Transplant Surgery | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (61.5 mi)
615-322-3000
Experience:
36+ years
Languages Spoken:
English, Arabic, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Bipin Savani is a Hematologist Oncology specialist and a Transplant Surgeon in Nashville, Tennessee. Dr. Savani has been practicing medicine for over 36 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Graft. Dr. Savani is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
View All 11 Elite Conditions
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile